These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9488831)

  • 1. Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela using the Etest method. The Venezuelan Antimicrobial Resistance Study Group.
    Pfaller MA; Jones RN; Doern GV
    Diagn Microbiol Infect Dis; 1998 Jan; 30(1):45-52. PubMed ID: 9488831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
    Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
    Jones RN; Salazar JC; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter evaluation of the antimicrobial activity for seven broad-spectrum beta-lactams in Turkey using the Etest method. Turkish Antimicrobial Resistance Study Group.
    Pfaller MA; Korten V; Jones RN; Doern GV
    Diagn Microbiol Infect Dis; 1999 Sep; 35(1):65-73. PubMed ID: 10529883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
    Jones RN; Pfaller MA; Doern GV; Erwin ME; Hollis RJ
    Diagn Microbiol Infect Dis; 1998 Mar; 30(3):215-28. PubMed ID: 9572029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum beta-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chinese Antimicrobial Resistance Study Group.
    Xu Y; Chen M; Biedenbach DJ; Deshpande LM; Jones RN
    Diagn Microbiol Infect Dis; 1999 Oct; 35(2):135-42. PubMed ID: 10579094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of cefepime and other broad-spectrum beta-lactams for isolates in Malaysia and Singapore medical centers. The Malaysia/Singapore Antimicrobial Resistance Study Group.
    Biedenbach DJ; Lewis MT; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):277-83. PubMed ID: 10668586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela: comparison of data from 1997 and 1998 using the Etest method. Venezuelan Antimicrobial Resistance Study Group.
    Pfaller MA; Jones RN; Doern GV
    Diagn Microbiol Infect Dis; 1999 Oct; 35(2):153-8. PubMed ID: 10579096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of broad-spectrum beta-lactams in the philippines medical centers: role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group.
    Johnson DM; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):291-7. PubMed ID: 10668588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group.
    Lewis MT; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):285-90. PubMed ID: 10668587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of antimicrobial susceptibility for beta-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006).
    Ishii Y; Tateda K; Yamaguchi K;
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):177-83. PubMed ID: 17931820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group.
    Lewis MT; Yamaguchi K; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):307-15. PubMed ID: 10668590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group.
    Doern GV; Jones RN; Pfaller MA; Erwin M; Ramirez-Rhonda C
    Diagn Microbiol Infect Dis; 1998 Feb; 30(2):113-9. PubMed ID: 9554179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of broad-spectrum beta-lactams tested in medical centers in Korea: role of fourth-generation cephalosporins. The Korean Antimicrobial Resistance Study Group.
    Lewis MT; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):317-23. PubMed ID: 10668591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008).
    Ishii Y; Ueda C; Kouyama Y; Tateda K; Yamaguchi K
    Diagn Microbiol Infect Dis; 2011 Apr; 69(4):443-8. PubMed ID: 21396543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus.
    Tallis E; Rudensky B; Attias D; Raveh D; Schlesinger Y; Yinnon AM
    Diagn Microbiol Infect Dis; 1999 Oct; 35(2):121-6. PubMed ID: 10579092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia: comparison of data from 1997 and 1998 using the Etest method. The Colombian Antimicrobial Resistance Study Group.
    Pfaller MA; Jones RN; Doern GV; Salazar JC
    Diagn Microbiol Infect Dis; 1999 Nov; 35(3):235-41. PubMed ID: 10626135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
    Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
    Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in eight medical centers in Thailand. The Thailand Antimicrobial Resistance Study Group.
    Biedenbach DJ; Johnson DM; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):325-31. PubMed ID: 10668592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.